PURPOSE: The favorable pharmacokinetics and clinical safety profile of metal-chelated 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) suggests that it might be an ideal hapten for pretargeted radioimmunotherapy. In an effort to minimize hapten retention in normal tissues and determine the effect of various chemical adducts on in vivo properties, a series of DOTA-based derivatives were evaluated. PROCEDURES: Biodistribution and whole-body clearance were evaluated for (177)Lu-labeled DOTA, DOTA-biotin, a di-DOTA peptide, and DOTA-aminobenzene in normal CD1 mice. Kidney, liver, and bone marrow doses were estimated using standard Medical Internal Radiation Dose methodology. RESULTS: All haptens demonstrated similar low tissue and whole-body retention, with 2-4% of the injected dose remaining in mice 4 h postinjection. The kidney is predicted to be dose limiting for all (177)Lu-labeled haptens tested with an estimated kidney dose of approximately 0.1 mGy/MBq. CONCLUSIONS: We present here a group of DOTA-based haptens that exhibit rapid clearance and exceptionally low whole-body retention 4 h postinjection. Aminobenzene, tyrosine-lysine, and biotin groups have minimal effects on the blood clearance and biodistribution of (177)Lu-DOTA.
PURPOSE: The favorable pharmacokinetics and clinical safety profile of metal-chelated 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) suggests that it might be an ideal hapten for pretargeted radioimmunotherapy. In an effort to minimize hapten retention in normal tissues and determine the effect of various chemical adducts on in vivo properties, a series of DOTA-based derivatives were evaluated. PROCEDURES: Biodistribution and whole-body clearance were evaluated for (177)Lu-labeled DOTA, DOTA-biotin, a di-DOTA peptide, and DOTA-aminobenzene in normal CD1mice. Kidney, liver, and bone marrow doses were estimated using standard Medical Internal Radiation Dose methodology. RESULTS: All haptens demonstrated similar low tissue and whole-body retention, with 2-4% of the injected dose remaining in mice 4 h postinjection. The kidney is predicted to be dose limiting for all (177)Lu-labeled haptens tested with an estimated kidney dose of approximately 0.1 mGy/MBq. CONCLUSIONS: We present here a group of DOTA-based haptens that exhibit rapid clearance and exceptionally low whole-body retention 4 h postinjection. Aminobenzene, tyrosine-lysine, and biotin groups have minimal effects on the blood clearance and biodistribution of (177)Lu-DOTA.
Authors: Krishnan Subbiah; Don K Hamlin; John M Pagel; D Scott Wilbur; Damon L Meyer; Don B Axworthy; Robert W Mallett; Louis J Theodore; Pat S Stayton; Oliver W Press Journal: J Nucl Med Date: 2003-03 Impact factor: 10.057
Authors: Kevin J Hamblett; Brian B Kegley; Don K Hamlin; Ming-Kuan Chyan; David E Hyre; Oliver W Press; D Scott Wilbur; Patrick S Stayton Journal: Bioconjug Chem Date: 2002 May-Jun Impact factor: 4.774
Authors: E Gautherot; E Rouvier; L Daniel; E Loucif; J Bouhou; C Manetti; M Martin; J M Le Doussal; J Barbet Journal: J Nucl Med Date: 2000-03 Impact factor: 10.057
Authors: D B Axworthy; J M Reno; M D Hylarides; R W Mallett; L J Theodore; L M Gustavson; F Su; L J Hobson; P L Beaumier; A R Fritzberg Journal: Proc Natl Acad Sci U S A Date: 2000-02-15 Impact factor: 11.205
Authors: R Haubner; H J Wester; F Burkhart; R Senekowitsch-Schmidtke; W Weber; S L Goodman; H Kessler; M Schwaiger Journal: J Nucl Med Date: 2001-02 Impact factor: 10.057
Authors: Robert M Sharkey; William J McBride; Habibe Karacay; Ken Chang; Gary L Griffiths; Hans J Hansen; David M Goldenberg Journal: Cancer Res Date: 2003-01-15 Impact factor: 12.701
Authors: Sarah M Cheal; Edward K Fung; Mitesh Patel; Hong Xu; Hong-Fen Guo; Pat B Zanzonico; Sebastien Monette; K Dane Wittrup; Nai-Kong V Cheung; Steven M Larson Journal: J Nucl Med Date: 2017-07-13 Impact factor: 10.057
Authors: Kelly D Orcutt; Gregory P Adams; Anna M Wu; Matthew D Silva; Catey Harwell; Jack Hoppin; Manabu Matsumura; Masakatsu Kotsuma; Jonathan Greenberg; Andrew M Scott; Robert A Beckman Journal: Mol Imaging Biol Date: 2017-10 Impact factor: 3.488
Authors: Neal K Devaraj; Greg M Thurber; Edmund J Keliher; Brett Marinelli; Ralph Weissleder Journal: Proc Natl Acad Sci U S A Date: 2012-03-12 Impact factor: 11.205
Authors: Kelly Davis Orcutt; John J Rhoden; Benjamin Ruiz-Yi; John V Frangioni; K Dane Wittrup Journal: Mol Cancer Ther Date: 2012-04-05 Impact factor: 6.261
Authors: Soomin Yoon; Yun-Hee Kim; Se Hun Kang; Seok-Ki Kim; Hwa Kyoung Lee; Hyori Kim; Junho Chung; In-Hoo Kim Journal: J Cancer Res Clin Oncol Date: 2013-12-01 Impact factor: 4.553
Authors: Sarah M Cheal; Hong Xu; Hong-Fen Guo; Sang-Gyu Lee; Blesida Punzalan; Sandhya Chalasani; Edward K Fung; Achim Jungbluth; Pat B Zanzonico; Jorge A Carrasquillo; Joseph O'Donoghue; Peter M Smith-Jones; K Dane Wittrup; Nai-Kong V Cheung; Steven M Larson Journal: Eur J Nucl Med Mol Imaging Date: 2015-11-24 Impact factor: 9.236
Authors: Sarah M Cheal; Hong Xu; Hong-fen Guo; Pat B Zanzonico; Steven M Larson; Nai-Kong Cheung Journal: Mol Cancer Ther Date: 2014-06-18 Impact factor: 6.261
Authors: Sarah M Cheal; Mitesh Patel; Guangbin Yang; Darren Veach; Hong Xu; Hong-Fen Guo; Pat B Zanzonico; Donald B Axworthy; Nai-Kong V Cheung; Ouathek Ouerfelli; Steven M Larson Journal: Bioconjug Chem Date: 2020-02-10 Impact factor: 4.774
Authors: Megan M Dacek; Darren R Veach; Sarah M Cheal; Lukas M Carter; Michael R McDevitt; Blesida Punzalan; Daniela Burnes Vargas; Thomas Z Kubik; Sebastien Monette; Brian H Santich; Guangbin Yang; Ouathek Ouerfelli; Adam L Kesner; Nai-Kong V Cheung; David A Scheinberg; Steven M Larson; Simone Krebs Journal: Bioconjug Chem Date: 2021-04-05 Impact factor: 4.774